Marker Therapeutics share price logo

Marker Therapeutics

NASDAQ: MRKR

$1.18

as on

Marker Therapeutics Stock Performance

as on September 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.17
    $1.23
    downward going graph

    0.85%

    Downside

    4.24%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.84
    $2.46
    downward going graph

    28.81%

    Downside

    108.47%

    Upside

    downward going graph

Marker Therapeutics share price movements today

Previous Close
$1.18
Open
$1.20
Volume
239.8K
Market Cap
$19.7M
Day's Low - High
$1.17 - $1.23
52 Week Low - High
$0.84 - $2.46

Marker Therapeutics Historical Returns

1 Month Return
-8.53 %
3 Month Return
-11.28 %
1 Year Return
+ 24.21 %
3 Year Return
-78.19 %
5 Year Return
-93.59 %

Marker Therapeutics Stock Fundamentals & Key Indicators

Check Marker Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$19.7M

EPS (TTM)

-0.48

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.46

Industry PE ratio

-2.37

PEG Ratio

-0.019619427636885695

EBITDA

-8.7M

Revenue (TTM)

1.2M

Profit Margin

-320.83%

Return On Equity TTM

-56.96%

Marker Therapeutics Stock Valuation

Track how Marker Therapeutics P/E has moved over time to understand its valuation trends.

Marker Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-5.88x)

December 31, 2023

Industry (-2.37x)

December 31, 2025

Today (-1.89x)

December 31, 2025

Highest (-0.74x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -1.89x

Marker Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Marker Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Marker Therapeutics image
Marker Therapeutics
BUY$19.7M-93.59%-2.46-320.83%0.00%
Moderna image
Moderna
BUY$63.1B-63.24%-19.81-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$130.1B174.21%29.8186.04%0.00%
Regeneron image
Regeneron
BUY$79.7B21.1%18.4884.86%0.48%

Stock Returns calculator for Marker Therapeutics Stock including INR - Dollar returns

The Marker Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Marker Therapeutics investment value today

Current value as on today

₹1,34,869

Returns

₹34,869

(+34.87%)

Returns from Marker Therapeutics Stock

₹24,211 (+24.21%)

Dollar Impact

₹10,658 (+10.66%)

Analyst Recommendation on Marker Therapeutics Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Marker Therapeutics. Average target price of $7.87

Marker Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Marker Therapeutics.

What analysts predicted

85.01%UPSIDE

Target Price

$7.87

Current Price

$1.18

Analyzed by

2 Analysts

Target

$7.87

Marker Therapeutics target price $7.87, a slight upside of 85.01% compared to current price of $1.18. According to 2 analysts rating.

Indian Investors' Interest in Marker Therapeutics Stock

Search interest for Marker Therapeutics Stock has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:100% versus previous 30 day period

Marker Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
1
1
1
1
0
0
1
-
-
-
Gross Profit
-1
-1
-1
-1
-2
-3
-1
-
-2
-
Operating Income
-2
-2
-2
-2
-4
-4
-2
-1
-4
-2
EBITDA
-2
0
0
-2
-
-4
-1
-1
-3
-1
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
2
2
-
4
0
-
-
-
-
Income Before Tax
-2
-2
-2
-2
-4
-4
-1
-1
-3
-1
Income Tax Expense
0
-
-
-
-
-
-
0
-
-
Net Income
-2
-2
-2
-2
-4
-4
-1
-1
-3
-1
Net Profit Margin
-147.73%
-106.98%
-99.74%
-80.22%
-798.14%
-385.04%
-90.26%
0.00%
0.00%
0.00%

Marker Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Mar 2025
Dec 2025
Total Revenue
0
0
0
0
1
3
3
6
-
Gross Profit
-5
-123
-12
-18
-1
-8
-7
-6
-
Operating Income
-11
-148
-22
-28
-39
-19
-14
-11
-12
EBITDA
-11
-147
-22
-27
-38
-16
-11
-10
-12
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
11
148
0
1
3
2
2
0
-
Income Before Tax
-10
-147
-21
-28
-41
-19
-14
-10
-12
Income Tax Expense
-
0
-
-
-
-
0
0
0
Net Income
-10
-147
-21
-28
-41
-29
-8
-10
-12
Net Profit Margin
-2768.43%
-60094.95%
-5887.41%
-3944.86%
-154.70%
-240.64%
-214.60%
-104.33%
0.00%

Marker Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-2
-2
-2
-2
-4
-4
-1
-1
-3
-1
Operating Cash Flow
-2
-3
-3
1
-5
-1
-2
-1
-1
-3
Investing Cash Flow
-
-
-
-
-
-
-
-
-
-
Financing Cash Flow
0
0
0
0
0
0
9
-
-
-
Change in Cash
-2
-3
-3
1
-5
-1
7
-1
-1
-3

Marker Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Mar 2025
Dec 2025
Net Income
-10
-147
-21
-28
-41
-19
-14
-10
-12
Operating Cash Flow
-8
-14
-18
-20
-27
-26
-16
-10
-12
Investing Cash Flow
-
0
0
-9
-3
-4
18
-
-
Financing Cash Flow
5
71
0
6
52
0
1
14
9
Change in Cash
-2
56
-17
-22
22
-31
3
4
-2

Mutual Funds that own Marker Therapeutics Stock

Check out the Mutual Funds with significant holdings in Marker Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
2.335009%
389319
Fidelity Concord Street Trust
0.664296%
110759

Global Institutional Holdings in Marker Therapeutics

Funds
Holdings
Vanguard
2.56%
Dennis J Purcell
1.95%
Scott Jarred
0.11%

Marker Therapeutics News & Key Events

    Insights on Marker Therapeutics

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Profit Spike

      img

      Netprofit is up for the last 2 quarters, -3.17M → -1.82M (in $), with an average increase of 74.1% per quarter

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 7 days, MRKR stock has moved up by 2.6%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Moderna, Inc. Common Stock has given 48.8% return, outperforming this stock by 126.7%

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Moderna, Inc. Common Stock has given 510.3% return, outperforming this stock by 486.1%

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 1.23M → 1.10M (in $), with an average decrease of 10.5% per quarter

    About Marker Therapeutics

    Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
    OrganisationMarker Therapeutics
    Headquarters2450 Holcombe Blvd, Houston, TX, 77021, US
    IndustryBiotechnology
    CEOJuan F. Vera
    E-voting on sharesClick here to vote

    Key Management of Marker Therapeutics

    Name

    Title

    Dr. Juan F. Vera M.D.

    Co-Founder, CEO, President, Treasurer, Secretary & Director

    Ms. Elizabeth Donnelly

    Director of Administration

    Dr. Maria-Bernadette Madel Ph.D.

    Director of Corporate Operations & External Communications

    Mr. Edmund Cheung

    Vice President of Human Resources

    Patricia Allison

    Head of Clinical Operations

    Ms. Mary Newman Ph.D.

    Head of Regulatory Affairs

    Dr. Robert Z. Florkiewicz Sr., Ph.D.

    Senior Director of Molecular Biology & Virology

    FAQs

    What is Marker Therapeutics share price today?

    Marker Therapeutics share price today is $1.18 as on at the close of the market. Marker Therapeutics share today touched a day high of $1.23 and a low of $1.17.

    What is the 52 week high and 52 week low for Marker Therapeutics share?

    Marker Therapeutics share touched a 52 week high of $2.46 on and a 52 week low of $0.84 on . Marker Therapeutics stock price today i.e. is closed at $1.18,which is 52.03% down from its 52 week high and 40.48% up from its 52 week low.

    What is Marker Therapeutics's market capitalisation today?

    Marker Therapeutics market capitalisation is $0.00T as on .

    How to invest in Marker Therapeutics Stock (MRKR) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Marker Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Marker Therapeutics Shares that will get you 1.2712 shares as per Marker Therapeutics share price of $1.18 per share as on September 19, 2026 at 8:45 am IST.

    What is the minimum amount required to buy Marker Therapeutics Stock (MRKR) from India?

    Indian investors can start investing in Marker Therapeutics (MRKR) shares with as little as ₹95.88 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹958.80 in Marker Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Marker Therapeutics share’s latest price of $1.18 as on September 19, 2026 at 8:45 am IST, you will get 8.4746 shares of Marker Therapeutics. Learn more about fractional shares .

    What are the returns that Marker Therapeutics has given to Indian investors in the last 5 years?

    Marker Therapeutics stock has given -93.59% share price returns and 30.25% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?